These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 17306533)

  • 1. Design and synthesis of novel prodrugs of 2'-deoxy-2'-methylidenecytidine activated by membrane dipeptidase overexpressed in tumor tissues.
    Kohchi Y; Hattori K; Oikawa N; Mizuguchi E; Isshiki Y; Aso K; Yoshinari K; Shirai H; Miwa M; Inagaki Y; Ura M; Ogawa K; Okabe H; Ishitsuka H; Shimma N
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2241-5. PubMed ID: 17306533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolidase, a potential enzyme target for melanoma: design of proline-containing dipeptide-like prodrugs.
    Mittal S; Song X; Vig BS; Landowski CP; Kim I; Hilfinger JM; Amidon GL
    Mol Pharm; 2005; 2(1):37-46. PubMed ID: 15804176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
    Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
    Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins.
    Ohsumi K; Hatanaka T; Nakagawa R; Fukuda Y; Morinaga Y; Suga Y; Nihei Y; Ohishi K; Akiyama Y; Tsuji T
    Anticancer Drug Des; 1999 Dec; 14(6):539-48. PubMed ID: 10834274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased cytotoxicity and increased antimitotic activity of a proline analogue of chlorambucil as a prodrug susceptible to the action of fibroblast's prolidase.
    Bielawska A; Chrzanowski K; Bielawski K; Pałka J
    Pharmazie; 2001 Apr; 56(4):290-4. PubMed ID: 11338665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity.
    Wang Y; Xin D; Liu K; Zhu M; Xiang J
    Bioconjug Chem; 2009 Dec; 20(12):2214-21. PubMed ID: 19950889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of oral 2'-deoxy-2'-methylidenecytidine: on a daily x 14-day schedule.
    Masuda N; Matsui K; Yamamoto N; Nogami T; Nakagawa K; Negoro S; Takeda K; Takifuji N; Yamada M; Kudoh S; Okuda T; Nemoto S; Ogawa K; Myobudani H; Nihira S; Fukuoka M
    Clin Cancer Res; 2000 Jun; 6(6):2288-94. PubMed ID: 10873079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleosides and nucleotides. 97. Synthesis of new broad spectrum antineoplastic nucleosides, 2'-deoxy-2'-methylidenecytidine (DMDC) and its derivatives.
    Matsuda A; Takenuki K; Tanaka M; Sasaki T; Ueda T
    J Med Chem; 1991 Feb; 34(2):812-9. PubMed ID: 1995905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
    Davies LC; Friedlos F; Hedley D; Martin J; Ogilvie LM; Scanlon IJ; Springer CJ
    J Med Chem; 2005 Aug; 48(16):5321-8. PubMed ID: 16078849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycosyl and polyalcoholic prodrugs of lonidamine.
    Giorgioni G; Ruggieri S; Di Stefano A; Sozio P; Cinque B; Di Marzio L; Santoni G; Claudi F
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2445-50. PubMed ID: 18321702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-immolative anthracycline prodrugs for suicide gene therapy.
    Niculescu-Duvaz I; Niculescu-Duvaz D; Friedlos F; Spooner R; Martin J; Marais R; Springer CJ
    J Med Chem; 1999 Jul; 42(13):2485-9. PubMed ID: 10395490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-molecule based delivery systems for alkylating antineoplastic compounds.
    Bielawski K; Bielawska A
    ChemMedChem; 2008 Apr; 3(4):536-42. PubMed ID: 18157855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of 2'-deoxy-2'-methylidenecytidine, a new 2'-deoxycytidine derivative.
    Yamagami K; Fujii A; Arita M; Okumoto T; Sakata S; Matsuda A; Ueda T; Sasaki T
    Cancer Res; 1991 May; 51(9):2319-23. PubMed ID: 2015596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
    Leu YL; Roffler SR; Chern JW
    J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of 2'-deoxy-2'-methylidenecytidine (DMDC), a deoxycytidine analogue antineoplastic agent.
    Brindley CJ; Morrison R; Gordon RJ; Devlin AJ; van der Gaast A; Verweij L; Funaki T
    Clin Pharmacokinet; 2000 Jun; 38(6):475-91. PubMed ID: 10885585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of anticancer prodrugs for reductive activation.
    Chen Y; Hu L
    Med Res Rev; 2009 Jan; 29(1):29-64. PubMed ID: 18688784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.
    Niculescu-Duvaz I; Scanlon I; Niculescu-Duvaz D; Friedlos F; Martin J; Marais R; Springer CJ
    J Med Chem; 2004 May; 47(10):2651-8. PubMed ID: 15115406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prodrug approach to the design of cRaf1 kinase inhibitors with improved cellular activity.
    Wood E; Crosby RM; Dickerson S; Frye SV; Griffin R; Hunter R; Jung DK; McDonald OB; McNutt R; Mahony WB; Peel MR; Ray J; Lackey K
    Anticancer Drug Des; 2001 Feb; 16(1):1-6. PubMed ID: 11762640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo antitumor activity of a novel nucleoside, 4'-thio-2'-deoxy-2'-methylidenecytidine.
    Miura S; Tanaka M; Yoshimura Y; Satoh H; Sakata S; Machida H; Matsuda A; Sasaki T
    Biol Pharm Bull; 1996 Oct; 19(10):1311-5. PubMed ID: 8913503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Antoniw P; Bagshawe KD; Wilman DE
    Anticancer Drug Des; 1991 Nov; 6(5):467-79. PubMed ID: 1764165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.